About GnuBIO
GnuBIO is a Healthcare company based in Cambridge (United States) founded in 2009, and was acquired by Bio Rad in April 2014. DNA sequencing platform using microfluidic technology is developed for diagnostics. GnuBIO has raised $21 million across 5 funding rounds from investors including HHS and Bio Rad. GnuBIO offers products and services including Sequencing Platform and Consumables. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is GNUBIO, INC. Its competitors include PacBio, Omniome and Complete Genomics; 3 of its 3 listed competitors have raised funding.
Company details
GnuBIO was founded in 2009 in Cambridge, United States, within the biotechnology sector. Emulsion-based microfluidic technology is utilized to create a scalable desktop sequencing system. This system supports analysis of single genes, gene panels, and whole genomes for diagnostic and applied markets. Operations focus on advancing DNA sequencing accessibility through integrated hardware and software solutions.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website gnubio.com
- Social LinkedIn
- Acquired by Bio Rad (Apr 2014)
- Legal Name Gnubio, Inc
Products & Services of GnuBIO
GnuBIO offers a comprehensive portfolio of products and services, including Sequencing Platform and Consumables.
Integrated system for rapid DNA sequencing and analysis
Supplies for operating the DNA sequencing platform
Funding Insights of GnuBIO
GnuBIO has successfully raised a total of $21M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in September 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21M
- Total Rounds 5
- Last Round Series B — $10M
- First Round $4.47M
(Sep 2010)
- Investors Count 1
All 5 funding rounds of GnuBIO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2012 | $10M | Series B | – | – | – |
| Sep 2012 | $4.5M | Grant | – | – | – |
| Dec 2010 | $3M | Series A | – | – | – |
| Nov 2010 | $8M | Series A | – | – | – |
| Sep 2010 | $4.47M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in GnuBIO
GnuBIO has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Bio Rad.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Portfolio of products and services for life science research and clinical diagnostic markets | 1952 | bio-rad.com | Hercules, United States |
Investor details for GnuBIO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GnuBIO
4 dated milestones of GnuBIO across 5 years, from founding to its latest funding, stage changes and deals.
- Founded GnuBIO is founded.
- Funding First funding round of $4.5M.
- Funding Latest funding round, Series B, of $10.0M.
- Exit Acquired by Bio Rad.
Competitors of GnuBIO
GnuBIO has 3 listed competitors in our database, 3 of them funded. They include PacBio, Omniome and Complete Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pacb.com | 2004 | Menlo Park, United States | $395M | 649 | Instrument systems and software for single-molecule real-time sequencing are developed. | |
| omniome.com | 2013 | San Diego, United States | $160.23M | 164 | Genome sequencing platform is provided for clinical diagnostics. | |
| completegenomics.com | 2006 | San Jose, United States | $124.99M | 70 | DNA sequencing platform for human genome analysis is developed. |
Detailed competitors of GnuBIO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GnuBIO (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gnubio
Complete news archive for GnuBIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GnuBIO
GnuBIO was founded in 2009 and raised its 1st funding round 1 year after it was founded.
GnuBIO is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
GnuBIO is a funded company, having raised a total of $21M across 5 funding rounds to date. The company's 1st funding round was a Grant of $4.47M, raised on Sep 2010.
GnuBIO was founded in 2009 in Cambridge, United States, within the biotechnology sector. Emulsion-based microfluidic technology is utilized to create a scalable desktop sequencing system. This system supports analysis of single genes, gene panels, and whole genomes for diagnostic and applied markets. Operations focus on advancing DNA sequencing accessibility through integrated hardware and software solutions.
GnuBIO's top competitors include PacBio, Complete Genomics and Omniome.
GnuBIO offers Sequencing Platform and Consumables.
GnuBIO operates through Gnubio, Inc.
Yes. GnuBIO was acquired by Bio Rad in April 2014.